Source: Annual Congress 2004 - Drug therapy of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Butorac Petanjek, D. Vrankovic, D. Pelicaric, M. Krizanic Jurisic, A. Rozman (Zagreb, Croatia). Our experiences in COPD treatment following GOLD implementation in Croatia. Eur Respir J 2004; 24: Suppl. 48, 1867

Member's Comments

No comment yet.

Related content which might interest you: GOLD recommendations for COPD management Source: International Congress 2014 – ERS/CTS China Day: advances in asthma and COPD Year: 2014 Adherence to GOLD guidelines practices in the management of COPD in  Tunisia Source: International Congress 2018 – COPD around the world Year: 2018 Romanian experience in running COPD awareness campaigns Source: International Congress 2016 – Public health related concerns and epidemiology of smoking and smoking-related products Year: 2016 Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Impact of the GOLD 2011 guidelines on treatment regimens in COPD patients Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 GOLD and phenotypes: The new Czech COPD guidelines Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 COPD: GOLD 2011 and implications for clinical practice Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 The distribution of COPD in UK general practice using the 2017 GOLD classification Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Distribution of COPD phenotypes according to the Spanish COPD guidelines in clinical practice Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 High risk COPD patients cost less if treated according to GOLD 2011 recommendations Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Implementation of the GOLD 2017 disease classification in a real-life COPD cohort Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Cost and effectiveness of 2 years integrated care intervention in COPD Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 New GOLD recommendations in a seven years follow up - changes in symptoms and risk categories Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Does NICE COPD audit tools affect management of COPD? Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013 The distribution of COPD in UK general practice using the new GOLD classification Source: Eur Respir J 2014; 43: 993-1002 Year: 2014 Three year follow-up of distribution and stability of patients with COPD according GOLD 2014 Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Rehabilitation programs in patients in different severity stage of COPD (GOLD II-to-IV): analysis of the results Source: Eur Respir J 2005; 26: Suppl. 49, 69s Year: 2005 COPD comorbidities and risk assessment according to GOLD 2011 revision Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Survival in three years of COPD patients according to GOLD 2003 and GOLD 2014 Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases Year: 2015